Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aquestive Therapeutics, Inc. (NASDAQ: AQST) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Aquestive uses current reports on Form 8‑K to announce material events such as quarterly financial results, new or updated investor presentations, patent developments for its Anaphylm™ epinephrine sublingual film, and financing agreements tied to future product revenues.
Through these filings, investors can review how Aquestive describes the status of its late-stage product candidate Anaphylm for severe allergic reactions, including anaphylaxis, and its earlier-stage epinephrine prodrug topical gel AQST‑108 for dermatologic conditions. Form 8‑K filings also reference press releases that discuss the FDA review process for the Anaphylm New Drug Application, regulatory interactions in Canada and Europe, and key milestones such as the FDA’s decision not to require an advisory committee meeting.
In addition, Aquestive’s 8‑K filings outline material definitive agreements, including a purchase and sale agreement with funds managed by RTW Investments LP that grants tiered revenue share rights on future U.S. net sales of Anaphylm, subject to conditions like FDA approval and debt refinancing. These documents describe covenants that affect the company’s ability to incur indebtedness and other obligations that may influence its capital structure.
On Stock Titan, users can view these filings as they are made available from EDGAR and use AI-powered summaries to understand the key points in lengthy documents. This includes highlights from earnings-related 8‑Ks, supplemental investor materials, and other disclosures that provide context on Aquestive’s financial condition, risk factors, product pipeline, and strategic initiatives. Filings related to insider activity, annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and additional 8‑Ks can all be analyzed with AI tools to quickly identify information relevant to AQST’s regulatory and business profile.
Aquestive Therapeutics, Inc. President and CEO Daniel Barber received a grant of 293,100 Performance Stock Units (PSUs) on March 7, 2025. Each PSU represents a contingent right to receive one share of common stock at no exercise price.
The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, will vest 100% on March 7, 2028. The award’s “Performance Price” is based on specified 30-day average Nasdaq closing prices during two measurement periods within this three-year term. The filing notes it was submitted late due to an inadvertent administrative oversight.
Boyd Peter E. reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics, Inc. reported that Chief People Officer Peter E. Boyd received a grant of 60,000 Performance Stock Units (PSUs) on March 7, 2025. Each PSU is a contingent right to receive one share of common stock if performance conditions are met.
The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, vest 100% on March 7, 2028. Performance is tied to specified 30-day average Nasdaq closing prices over two measurement periods. The filing notes it was submitted late due to an inadvertent administrative oversight.
Jung Cassie reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics Chief Operating Officer Cassie Jung received a grant of 60,000 Performance Stock Units (PSUs), each tied to one share of common stock. The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, vest 100% on March 7, 2028.
The award’s payout depends on the company’s share price over two multi-year periods, using defined 30‑day average Nasdaq closing prices. After this grant, Jung directly holds 60,000 PSUs, and there were no reported open‑market buys or sells in this filing.
TOTH A ERNEST JR reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics reported that its SVP and Chief Financial Officer, Ernest A. Toth Jr., received a grant of 82,500 Performance Stock Units (PSUs) on March 7, 2025 as equity compensation. Each PSU gives a contingent right to one share of common stock, vesting 100% on March 7, 2028 if performance conditions are met.
The PSUs measure stock performance between March 7, 2025 and March 7, 2028 using defined 30‑day average Nasdaq closing price periods. This was a direct award, not an open‑market purchase or sale. The Form 4 notes it was filed late due to an inadvertent administrative oversight.
Korczynski Sherry reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics reported that Chief Commercial Officer Sherry Korczynski received a grant of 67,500 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of common stock, with no cash paid by the executive at grant.
The PSUs measure performance from March 7, 2025 through March 7, 2028 and, if earned, will vest 100% on March 7, 2028. Performance is tied to a defined “Performance Price,” based on 30‑day average Nasdaq closing prices over two measurement periods, aligning the award’s value with the company’s share performance.
BRAENDER LORI J reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics, Inc. Corporate Secretary Lori J. Braender received a grant of 82,500 Performance Stock Units on March 7, 2025. Each unit represents a contingent right to one share of common stock and measures performance from March 7, 2025 through March 7, 2028.
If earned under the performance formula, the units vest 100% on March 7, 2028, with the award expiring on that date. The filing notes it was submitted late due to an inadvertent administrative oversight.
Aquestive Therapeutics, Inc. filed a Form 3 for Chief Legal Officer Thomas A. Zalewski. The filing lists a holding entry in common stock, with total common shares beneficially owned directly reported as 0 following the reported entry.
Aquestive Therapeutics filed an 8-K after completing an in-person FDA Type A meeting on its Anaphylm™ (dibutepinephrine) sublingual film program for treating Type 1 allergic reactions, including anaphylaxis. The meeting provided preliminary FDA feedback on pharmacokinetic and human factors study designs and on revised packaging.
The company says it is incorporating the FDA’s comments into upcoming studies and plans to submit the human factors protocol for FDA review. Based on this interaction, Aquestive reaffirmed its plan to resubmit the Anaphylm New Drug Application in the third quarter of 2026 and is also advancing regulatory submissions in Canada and the European Union.
Aquestive Therapeutics is reshaping its legal leadership, appointing Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026, while Lori J. Braender steps down from those executive roles and continues as Corporate Secretary.
Braender will provide transition services and receive her current base salary through May 7, 2026, plus a pro rata 2026 bonus, 12 months of severance-style monthly payments equal to 1/12 of her prior base salary and target bonus, and 12 months of continued health and life insurance coverage. All of her unvested equity awards will fully vest on May 7, 2026, and options and similar awards will remain exercisable for at least five years or until their scheduled expirations.
For her ongoing non-executive role, Braender will earn a base salary of $15,000 per month and remain eligible for senior executive benefit plans. To induce Zalewski to join, the company will grant 100,000 Restricted Stock Units and 75,000 stock options under its 2022 Equity Inducement Plan, vesting over three years, with the options carrying a ten-year term and an exercise price set at the closing price on May 8, 2026.
Aquestive Therapeutics Chief People Officer Peter E. Boyd reported equity awards and a mandated tax-related share sale. On March 9, he received 80,000 shares of restricted Common Stock that vest over three annual installments (25%, 25%, 50%), and a non-qualified stock option for 42,500 shares of Common Stock at $4.29 per share, expiring on March 9, 2036, with the same vesting pattern.
On March 10, 29,814 shares of Common Stock were sold at a weighted average price of $4.173 per share solely to cover tax withholding obligations tied to restricted stock unit vesting, as required by the company’s equity plans and not as discretionary trading. After these transactions, Boyd directly holds 338,509 shares of Common Stock plus the newly granted option for 42,500 shares.